JP2017533192A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017533192A5 JP2017533192A5 JP2017519649A JP2017519649A JP2017533192A5 JP 2017533192 A5 JP2017533192 A5 JP 2017533192A5 JP 2017519649 A JP2017519649 A JP 2017519649A JP 2017519649 A JP2017519649 A JP 2017519649A JP 2017533192 A5 JP2017533192 A5 JP 2017533192A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- interferon
- treatment period
- composition according
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 31
- 102000002227 Interferon Type I Human genes 0.000 claims 13
- 108010014726 Interferon Type I Proteins 0.000 claims 13
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 7
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 5
- 210000000265 leukocyte Anatomy 0.000 claims 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 2
- 102000006992 Interferon-alpha Human genes 0.000 claims 2
- 108010047761 Interferon-alpha Proteins 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000000524 functional group Chemical group 0.000 claims 2
- 238000005534 hematocrit Methods 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 229920001427 mPEG Polymers 0.000 claims 2
- 206010028537 myelofibrosis Diseases 0.000 claims 2
- 208000037244 polycythemia vera Diseases 0.000 claims 2
- 229920000642 polymer Polymers 0.000 claims 2
- 206010000830 Acute leukaemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000025321 B-lymphoblastic leukemia/lymphoma Diseases 0.000 claims 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 238000004820 blood count Methods 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000019420 lymphoid neoplasm Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 201000006462 myelodysplastic/myeloproliferative neoplasm Diseases 0.000 claims 1
- 238000010606 normalization Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 0 C*C(*[Mn])(*(CI)N)[C@@](*)(C(C)C(*)(*)C(C)N)NP Chemical compound C*C(*[Mn])(*(CI)N)[C@@](*)(C(C)C(*)(*)C(C)N)NP 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14192114.8 | 2014-11-06 | ||
| EP14192114 | 2014-11-06 | ||
| PCT/US2015/059410 WO2016073825A1 (en) | 2014-11-06 | 2015-11-06 | Dosage regimen for pegylated interferon |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020151877A Division JP2021001184A (ja) | 2014-11-06 | 2020-09-10 | ペグ化インターフェロンのための投薬計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017533192A JP2017533192A (ja) | 2017-11-09 |
| JP2017533192A5 true JP2017533192A5 (enExample) | 2018-11-29 |
| JP6820841B2 JP6820841B2 (ja) | 2021-01-27 |
Family
ID=51945707
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017519649A Active JP6820841B2 (ja) | 2014-11-06 | 2015-11-06 | ペグ化インターフェロンのための投薬計画 |
| JP2020151877A Withdrawn JP2021001184A (ja) | 2014-11-06 | 2020-09-10 | ペグ化インターフェロンのための投薬計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020151877A Withdrawn JP2021001184A (ja) | 2014-11-06 | 2020-09-10 | ペグ化インターフェロンのための投薬計画 |
Country Status (32)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018134260A1 (en) * | 2017-01-18 | 2018-07-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment patients suffering from myeloproliferative disorders |
| US11414698B2 (en) * | 2018-03-22 | 2022-08-16 | Chang Gung Medical Foundation Chang Gung Memorial Hospital At Chiayi | Method of quantifying mutant allele burden of target gene |
| US20230131808A1 (en) * | 2020-04-22 | 2023-04-27 | Southlake Pharmaceuticals, Inc. | Pegylated interferon tau and compositions and methods thereof |
| AU2022221496A1 (en) * | 2021-08-29 | 2023-03-16 | Pharmaessentia Corporation | Method of Using Pegylated Interferon-alpha |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| US5951974A (en) | 1993-11-10 | 1999-09-14 | Enzon, Inc. | Interferon polymer conjugates |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US5738846A (en) | 1994-11-10 | 1998-04-14 | Enzon, Inc. | Interferon polymer conjugates and process for preparing the same |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| TW517067B (en) | 1996-05-31 | 2003-01-11 | Hoffmann La Roche | Interferon conjugates |
| US6824768B2 (en) * | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
| RU2002105485A (ru) * | 1999-08-13 | 2004-01-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α) |
| WO2001015736A2 (en) | 1999-08-27 | 2001-03-08 | Maxygen Aps | Interferon-beta conjugates |
| KR20020065517A (ko) | 1999-11-12 | 2002-08-13 | 맥시겐 홀딩스 리미티드 | 인터페론 감마 접합체 |
| US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
| OA13063A (en) | 2001-11-20 | 2006-11-10 | Pharmacia Corp | Chemically-modified human growth hormone conjugates. |
| US20030171285A1 (en) | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| BRPI0306993B8 (pt) | 2002-01-18 | 2021-05-25 | Biogen Idec Inc | polímero de polialquilenoglicol ativado; composição; e uso de um composto na produção de um medicamento para o tratamento de esclerose múltipla ou infecção viral suscetível |
| US7345150B2 (en) | 2002-03-26 | 2008-03-18 | Medical University Of Toledo | Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use |
| EP1546235B1 (en) | 2002-09-09 | 2021-10-20 | Nektar Therapeutics | Water-soluble polymer alkanals |
| US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| TWI364295B (en) | 2002-12-26 | 2012-05-21 | Mountain View Pharmaceuticals | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| KR101128320B1 (ko) | 2003-05-23 | 2012-04-12 | 넥타르 테라퓨틱스 | 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체 |
| CA2547140A1 (en) | 2003-11-24 | 2005-06-09 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| CN101010105A (zh) | 2004-08-31 | 2007-08-01 | 法玛西雅厄普约翰有限责任公司 | 甘油支化的聚乙二醇人生长激素缀合物、其制备方法及其使用方法 |
| US7365127B2 (en) | 2005-02-04 | 2008-04-29 | Enzon Pharmaceuticals, Inc. | Process for the preparation of polymer conjugates |
| EP1869079A2 (en) | 2005-03-11 | 2007-12-26 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| WO2006094530A1 (en) | 2005-03-11 | 2006-09-14 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| CN101002944B (zh) | 2006-01-17 | 2012-07-25 | 中国科学院过程工程研究所 | 支链聚乙二醇-干扰素结合物及其制备方法 |
| EP1834963A1 (en) | 2006-03-13 | 2007-09-19 | Siegfried Ltd. | Di-polymer protein conjugates and processes for their preparation |
| CN101104078B (zh) | 2006-07-11 | 2011-11-02 | 北京美倍他药物研究有限公司 | 多肽及蛋白药物的聚乙二醇偶合物 |
| CN101108895B (zh) | 2006-07-19 | 2011-10-26 | 北京键凯科技有限公司 | 聚乙二醇乙醛衍生物及其与药物的结合物 |
| WO2008021487A1 (en) * | 2006-08-18 | 2008-02-21 | Pepgen Corporation | Combination treatment method with interferon-tau |
| CN1966547B (zh) | 2006-11-06 | 2011-11-09 | 中国药科大学 | 双链结构的聚乙二醇衍生物的制备及其与药物分子的结合 |
| CN1970572A (zh) | 2006-12-21 | 2007-05-30 | 北京三元基因工程有限公司 | 干扰素α突变体及其聚乙二醇衍生物 |
| CL2008002399A1 (es) | 2007-08-16 | 2009-01-02 | Pharmaessentia Corp | Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c. |
| ES2382124T3 (es) * | 2007-09-04 | 2012-06-05 | Biosteed Gene Expression Tech. Co., Ltd. | Interferón alfa 2b modificado con polietilenglicol y método de preparación y aplicaciones de este |
| CA2698396C (en) | 2007-09-04 | 2014-01-21 | Biosteed Gene Expression Tech. Co., Ltd. | Interferon alpha2a modified by polyethylene glycol, the preparation and use thereof |
| CN101491682A (zh) | 2008-04-30 | 2009-07-29 | 北京凯正生物工程发展有限责任公司 | 聚乙二醇化重组人干扰素ω偶合物及其制备工艺 |
| CN102131844B (zh) | 2008-07-31 | 2016-03-02 | 药华医药股份有限公司 | 肽-聚合物缀合物 |
| CN101671390B (zh) | 2008-09-10 | 2012-10-03 | 海南四环心脑血管药物研究院有限公司 | 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途 |
| CN101514229B (zh) | 2009-04-03 | 2012-05-09 | 海南四环心脑血管药物研究院有限公司 | 人干扰素α衍生物及其聚乙二醇化修饰物 |
| UA109646C2 (uk) | 2009-12-10 | 2015-09-25 | Терапевтичне застосування кон'югатів білка з полімером | |
| CN103328038A (zh) | 2010-12-01 | 2013-09-25 | 史拜诺莫度雷森公司 | 向神经解剖结构直接递送药剂 |
-
2015
- 2015-11-06 JP JP2017519649A patent/JP6820841B2/ja active Active
- 2015-11-06 SM SM20240028T patent/SMT202400028T1/it unknown
- 2015-11-06 SI SI201531980T patent/SI3215193T1/sl unknown
- 2015-11-06 TW TW104136693A patent/TWI737583B/zh active
- 2015-11-06 LT LTEPPCT/US2015/059410T patent/LT3215193T/lt unknown
- 2015-11-06 EP EP15857703.1A patent/EP3215193B1/en active Active
- 2015-11-06 AU AU2015342908A patent/AU2015342908B2/en active Active
- 2015-11-06 KR KR1020237018405A patent/KR102724837B1/ko active Active
- 2015-11-06 BR BR112017009193-3A patent/BR112017009193A2/pt not_active Application Discontinuation
- 2015-11-06 MX MX2017005244A patent/MX389844B/es unknown
- 2015-11-06 UA UAA201705540A patent/UA122867C2/uk unknown
- 2015-11-06 RS RS20231262A patent/RS65015B1/sr unknown
- 2015-11-06 HR HRP20231732TT patent/HRP20231732T1/hr unknown
- 2015-11-06 MY MYPI2017701335A patent/MY191506A/en unknown
- 2015-11-06 HU HUE15857703A patent/HUE064909T2/hu unknown
- 2015-11-06 ES ES15857703T patent/ES2966888T3/es active Active
- 2015-11-06 PH PH1/2017/500617A patent/PH12017500617B1/en unknown
- 2015-11-06 DK DK15857703.1T patent/DK3215193T3/da active
- 2015-11-06 EP EP23199969.9A patent/EP4282485A3/en active Pending
- 2015-11-06 FI FIEP15857703.1T patent/FI3215193T3/fi active
- 2015-11-06 SG SG11201702798PA patent/SG11201702798PA/en unknown
- 2015-11-06 CN CN201580058159.1A patent/CN107530403A/zh active Pending
- 2015-11-06 CA CA2964390A patent/CA2964390A1/en active Pending
- 2015-11-06 NZ NZ730924A patent/NZ730924A/en unknown
- 2015-11-06 EA EA201790991A patent/EA037151B1/ru unknown
- 2015-11-06 HK HK18102667.8A patent/HK1243627A1/zh unknown
- 2015-11-06 WO PCT/US2015/059410 patent/WO2016073825A1/en not_active Ceased
- 2015-11-06 US US15/518,423 patent/US11559567B2/en active Active
- 2015-11-06 KR KR1020177015233A patent/KR102540109B1/ko active Active
- 2015-11-06 PL PL15857703.1T patent/PL3215193T3/pl unknown
- 2015-11-06 PT PT158577031T patent/PT3215193T/pt unknown
-
2017
- 2017-04-06 IL IL251627A patent/IL251627B/en unknown
- 2017-04-18 ZA ZA2017/02704A patent/ZA201702704B/en unknown
- 2017-05-02 CL CL2017001088A patent/CL2017001088A1/es unknown
-
2020
- 2020-09-10 JP JP2020151877A patent/JP2021001184A/ja not_active Withdrawn
-
2022
- 2022-12-23 US US18/088,272 patent/US12343381B2/en active Active
-
2025
- 2025-02-21 US US19/059,883 patent/US20250186552A1/en active Pending